XML 20 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Revenue Recognized under Various Agreements (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Dec. 31, 2011
Dec. 31, 2008
Glaxo, Smith, Kline
Jun. 30, 2014
Glaxo, Smith, Kline
Jun. 30, 2013
Glaxo, Smith, Kline
Jun. 30, 2014
Glaxo, Smith, Kline
Jun. 30, 2013
Glaxo, Smith, Kline
Jun. 30, 2014
Astra Zeneca
Jun. 30, 2013
Astra Zeneca
Jun. 30, 2014
Astra Zeneca
Jun. 30, 2013
Astra Zeneca
Jun. 30, 2014
National Institute Of Allergy And Infectious Diseases
Jun. 30, 2013
National Institute Of Allergy And Infectious Diseases
Jun. 30, 2014
National Institute Of Allergy And Infectious Diseases
Jun. 30, 2013
National Institute Of Allergy And Infectious Diseases
Jun. 30, 2014
National Institutes of Health
Jun. 30, 2013
National Institutes of Health
Jun. 30, 2014
National Institutes of Health
Jun. 30, 2013
National Institutes of Health
Product Information [Line Items]                                            
Initial payment           $ 10,000 $ 631 $ 357 $ 1,262 $ 714 $ 180 $ 180 $ 360 $ 360                
Subsequent payment                     675   1,350                  
Milestone revenue         12,000           545 819 1,432 1,165                
Total revenues 3,048 3,392 6,546 5,477     631 357 1,262 714 1,400 999 3,142 1,525                
Grant revenue $ 1,007 $ 1,395 $ 2,132 $ 2,155                     $ 965 $ 1,062 $ 1,839 $ 1,660 $ 42 $ 333 $ 293 $ 495